Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1968 Sep;34(1):43–55. doi: 10.1111/j.1476-5381.1968.tb07949.x

The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias

A M Barrett, Valerie A Cullum
PMCID: PMC1703450  PMID: 19108278

Abstract

1. The optical isomers of propranolol have been compared for their β-blocking and antiarrhythmic activities.

2. In blocking the positive inotropic and chronotropic responses to isoprenaline, (+)-propranolol had less than one hundredth the potency of (-)-propranolol. At dose levels of (+)-propranolol which attenuated the responses to isoprenaline, there was a significant prolongation of the PR interval of the electrocardiogram.

3. The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol. (+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose.

4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.

5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.

6. Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09±0.02 mg/kg whereas that of (+)-propranolol was 4.2±1.2 mg/kg. At the effective dose level of (+)-propranolol there was a significant prolongation of the PR interval of the electrocardiogram. Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.

7. Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs. The dose of (-)-propranolol was significantly smaller than that of (+)-propranolol in both species but much higher than that required to produce evidence of β-blockade.

8. The implications of these results are discussed.

Full text

PDF
43

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberg G., Welin I. Interaction of beta-receptor blocking agents with the nerve blocking effects of procaine in vitro. Life Sci. 1967 May 1;6(9):975–979. doi: 10.1016/0024-3205(67)90084-7. [DOI] [PubMed] [Google Scholar]
  2. Antonis A., Clark M. L., Hodge R. L., Molony M., Pilkington T. R. Receptor mechanisms in the hyperglycaemic response to adrenaline in man. Lancet. 1967 May 27;1(7500):1135–1137. doi: 10.1016/s0140-6736(67)91710-2. [DOI] [PubMed] [Google Scholar]
  3. Barrett A. M., Crowther A. F., Dunlop D., Shanks R. G., Smith L. H. Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1968;259(2):152–153. doi: 10.1007/BF00537746. [DOI] [PubMed] [Google Scholar]
  4. Barrett A. M., Thorp J. M. Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs. Br J Pharmacol Chemother. 1968 Feb;32(2):381–391. doi: 10.1111/j.1476-5381.1968.tb00980.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Björntorp P., Ek L., Olsson S., Schröder G. The effect of a beta-adrenergic receptor antagonist (H 56-28) on lipid mobilization. Acta Pharmacol Toxicol (Copenh) 1967;25:51–62. [PubMed] [Google Scholar]
  6. Blinks J. R. Convenient apparatus for recording contractions of isolated heart muscle. J Appl Physiol. 1965 Jul;20(4):755–757. doi: 10.1152/jappl.1965.20.4.755. [DOI] [PubMed] [Google Scholar]
  7. Dunlop D., Shanks R. G. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968 Jan;32(1):201–218. doi: 10.1111/j.1476-5381.1968.tb00444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. GILL E. W., WILLIAMS E. M. LOCAL ANAESTHETIC ACTIVITY OF THE BETA-RECEPTOR ANTAGONIST, PRONETHALOL. Nature. 1964 Jan 11;201:199–199. doi: 10.1038/201199a0. [DOI] [PubMed] [Google Scholar]
  9. GRAYSON J., JOHNSON D. H. The effect of adrenaline and noradrenaline on the liver blood flow. J Physiol. 1953 Apr 28;120(1-2):73–94. doi: 10.1113/jphysiol.1953.sp004874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Howe R., Shanks R. G. Optical isomers of propranolol. Nature. 1966 Jun 25;210(5043):1336–1338. doi: 10.1038/2101336a0. [DOI] [PubMed] [Google Scholar]
  11. LEVY B., AHLQUIST R. P. An analysis of adrenergic blocking activity. J Pharmacol Exp Ther. 1961 Aug;133:202–210. [PubMed] [Google Scholar]
  12. LUCCHESI B. R. THE ACTION OF NETHALIDE UPON EXPERIMENTALLY INDUCED CARDIAC ARRHYTHMIAS. J Pharmacol Exp Ther. 1964 Sep;145:286–291. [PubMed] [Google Scholar]
  13. LUCCHESI B. R. THE EFFECTS OF PRONETHALOL AND ITS DEXTRO ISOMER UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS. J Pharmacol Exp Ther. 1965 Apr;148:94–99. [PubMed] [Google Scholar]
  14. Lish P. M., Weikel J. H., Dungan K. W. Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1965 Aug;149(2):161–173. [PubMed] [Google Scholar]
  15. Lucchesi B. R., Whitsitt L. S., Brown N. L. Propranolol (Inderal) in experimentally-induced cardiac arrhythmias. Can J Physiol Pharmacol. 1966 Jul;44(4):543–547. doi: 10.1139/y66-069. [DOI] [PubMed] [Google Scholar]
  16. Parmley W. W., Braunwald E. Comparative myocardial depressant and anti-arrhythmic properties of d-propranolol, dl-propranolol and quinidine. J Pharmacol Exp Ther. 1967 Oct;158(1):11–21. [PubMed] [Google Scholar]
  17. SEKIYA A., VAUGHANWILLIAMS E. M. A COMPARISON OF THE ANTIFIBRILLATORY ACTIONS AND EFFECTS ON INTRACELLULAR CARDIAC POTENTIALS OF PRONETHALOL, DISOPYRAMIDE AND QUINIDINE. Br J Pharmacol Chemother. 1963 Dec;21:473–481. doi: 10.1111/j.1476-5381.1963.tb02015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Salvador R. A., April S. A., Lemberger L. Inhibition by butoxamine, propranolol and MJ1999 of the glycogenolytic action of the catecholamines in the rat. Biochem Pharmacol. 1967 Oct;16(10):2037–2041. doi: 10.1016/0006-2952(67)90319-x. [DOI] [PubMed] [Google Scholar]
  19. Shanks R. G. The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother. 1967 Feb;29(2):204–217. doi: 10.1111/j.1476-5381.1967.tb01953.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Whitsitt L. S., Lucchesi B. R. The cardiac beta-adrenergic receptor blocking actions of propranolol and its stereoisomers. Life Sci. 1967 May 1;6(9):939–950. doi: 10.1016/0024-3205(67)90080-x. [DOI] [PubMed] [Google Scholar]
  21. Zsoter T., Tom H., Kraml M., Dvornik D. Adrenergic beta receptors and plasma free fatty acids. J Pharmacol Exp Ther. 1966 Jun;152(3):425–431. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES